Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ontamalimab - Takeda

Drug Profile

Ontamalimab - Takeda

Alternative Names: PF-00547659; PF-547659; SHP647

Latest Information Update: 11 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Takeda
  • Class Anti-inflammatories; Antiulcers; Monoclonal antibodies
  • Mechanism of Action Alpha4beta7 integrin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis; Crohn's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Crohn's disease; Ulcerative colitis

Most Recent Events

  • 04 Apr 2019 Phase-III clinical trials in Crohn's disease in Ukraine, South Korea (SC) as at April 2019 (NCT03627091; EudraCT2017-000617-23)
  • 18 Mar 2019 Phase-III clinical trials in Crohn's disease in Slovakia, Japan, Germany, Croatia, Australia, Portugal, Estonia, Greece (SC) as at March 2019 (NCT03627091; EudraCT2017-000617-23)
  • 18 Mar 2019 Shire initiates the phase III CARMEN CD 307 trial in Crohn's disease in USA, Bulgaria, Hungary, Lithuania, Spain, the Netherlands, Austria, Belgium, Poland (NCT03627091; EudraCT2017-000617-23)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top